Abaxis (ABAX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2016 and Declares a 9% Increase in Quarterly Cash Dividend
April 28, 2016 4:02 PM EDTUNION CITY, Calif., April 28, 2016 /PRNewswire/ --Â Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company manufacturing point-of-care blood analysis instruments and consumables for the medical and veterinary markets worldwide, today reported financial results for the fourth quarter and fiscal year ended March 31, 2016.
Fourth quarter and fiscal 2016 overview:
Revenues from continuing operations of $57.0 million for the fourth quarter, up 10% over last year's comparable quarter, and $218.9 million for fiscal 2016, up 8% year-over-year. Diluted EPS from continuing operations of $0.36 for the fourth quarter, up 112% over last year's comparable quarter, and $1.36 for fiscal 2016, up 49%... More